{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:34:50Z","timestamp":1789425290777,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009098","name":"Japanese Respiratory Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009098","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.resinv.2025.05.005","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T16:10:37Z","timestamp":1747411837000},"page":"633-638","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Exploring factors associated with clinical remission in patients with severe asthma receiving anti-IL-4R\u03b1, anti-IL-5\/5R, or anti-IgE treatment"],"prefix":"10.1016","volume":"63","author":[{"given":"Shota","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7481-0212","authenticated-orcid":false,"given":"Naoya","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Marumo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2574-2516","authenticated-orcid":false,"given":"Yu","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyohei","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon Hee","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Sunadome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuyasu","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Murohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8754-6318","authenticated-orcid":false,"given":"Hisako","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7431-9044","authenticated-orcid":false,"given":"Toyohiro","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2025.05.005_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1164\/rccm.202109-2205PP","article-title":"Global initiative for asthma strategy 2021: executive summary and rationale for key changes","volume":"205","author":"Reddel","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2025.05.005_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.alit.2022.11.008","article-title":"Biologics for severe asthma: the real-world evidence, effectiveness of switching, and prediction factors for the efficacy","volume":"72","author":"Nagase","year":"2023","journal-title":"Allergol Int"},{"key":"10.1016\/j.resinv.2025.05.005_bib3","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.jaip.2024.03.049","article-title":"Long-term effectiveness of anti-IL-4R therapy following suboptimal response to anti-IL-5\/5R therapy in severe eosinophilic asthma","volume":"12","author":"Gates","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.resinv.2025.05.005_bib4","article-title":"Clinical remission with biologic therapies in severe asthma: a matter of definition","volume":"63","author":"Registry","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2025.05.005_bib5","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00819-2023","article-title":"Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry","volume":"62","author":"McDowell","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2025.05.005_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12082900","article-title":"A real-world study of achievement rate and predictive factors of clinical and deep remission to biologics in patients with severe asthma","volume":"12","author":"Oishi","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.resinv.2025.05.005_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1150162","article-title":"Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: analysis of the REDES study","volume":"14","author":"Pavord","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.resinv.2025.05.005_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107720","article-title":"Dupilumab responder types and predicting factors in patients with type 2 severe asthma: a real-world cohort study","volume":"231","author":"Bult","year":"2024","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2025.05.005_bib9","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.chest.2023.10.046","article-title":"Clinical response and remission in patients with severe asthma treated with biologic therapies","volume":"165","author":"Hansen","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2025.05.005_bib10","year":"2024","journal-title":"Global Strategy for Asthma Management and Prevention"},{"key":"10.1016\/j.resinv.2025.05.005_bib11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.200801-060ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice","volume":"180","author":"Reddel","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2025.05.005_bib12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaci.2003.09.008","article-title":"Development of the asthma control test: a survey for assessing asthma control","volume":"113","author":"Nathan","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2025.05.005_bib13","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(23)00415-0","article-title":"Pioneering a paradigm shift in asthma management: remission as a treatment goal","volume":"12","author":"Lommatzsch","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2025.05.005_bib14","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.resinv.2024.10.009","article-title":"A protocol for a Japanese prospective cohort evaluating the features of patients with uncontrolled asthma achieving clinical remission: j-circle","volume":"62","author":"Tanabe","year":"2024","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2025.05.005_bib15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2025.05.005_bib16","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.resinv.2014.03.003","article-title":"Reference values for spirometry, including vital capacity, in Japanese adults calculated with the LMS method and compared with previous values","volume":"52","author":"Kubota","year":"2014","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2025.05.005_bib17","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2025.05.005_bib18","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1164\/rccm.202311-2192OC","article-title":"Exploring definitions and predictors of severe asthma clinical remission after biologic treatment in adults","volume":"210","author":"Perez-de-Llano","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2025.05.005_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13010291","article-title":"Clinical remission in patients affected by severe eosinophilic asthma on dupilumab therapy: a long-term real-life study","volume":"13","author":"Quarato","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.resinv.2025.05.005_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107348","article-title":"Severe asthma clinical remission after biologic treatment with anti-IL4\/IL13: a real-life experience","volume":"217","author":"Portacci","year":"2023","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2025.05.005_bib21","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.05.005_bib22","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.05.005_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1121237","article-title":"Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps","volume":"14","author":"Pelaia","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.resinv.2025.05.005_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2024.07.001","article-title":"Efficacy of dupilumab for severe chronic rhinosinusitis with nasal polyps and asthma: a prospective study","volume":"133","author":"Tajiri","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.resinv.2025.05.005_bib25","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00936-2018","article-title":"Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma","volume":"52","author":"Bleecker","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2025.05.005_bib26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12931-021-01746-4","article-title":"Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions","volume":"22","author":"Gibson","year":"2021","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2025.05.005_bib27","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4168\/aair.2021.13.2.219","article-title":"Sex differences in severe asthma: results from severe asthma network in Italy-sani","volume":"13","author":"Senna","year":"2021","journal-title":"Allergy Asthma Immunol Res"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534525000693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534525000693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T23:50:43Z","timestamp":1749599443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534525000693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2212534525000693"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2025.05.005","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring factors associated with clinical remission in patients with severe asthma receiving anti-IL-4R\u03b1, anti-IL-5\/5R, or anti-IgE treatment","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2025.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Japanese Respiratory Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}